Experimental COVID Treatment, Derived From Llamas, Shows Promise.<br />According to the BBC, early trials of a COVID-19 therapy derived from a llama named Fifi has shown, "significant potential.".<br />The experimental research was done at <br />the Rosalind Franklin Institute in Oxfordshire, England.<br />The experimental research was done at <br />the Rosalind Franklin Institute in Oxfordshire, England.<br />The team's work has shown <br />that coronavirus-infected <br />rodents treated with a <br />new nanobody nasal spray<br />fully recovered within six days.<br />The BBC points out that the treatment <br />has only been tested in lab animals.<br />but Public Health England said it was among the, "most effective SARS-CoV-2 <br />neutralizing agents" tested to date.<br />Similar to antibodies, virus-specific nanobodies bind to viruses and bacteria and help the body's immune system target them for destruction.<br />By vaccinating Fifi with a tiny, non-infectious piece <br />of the viral protein, the scientists stimulated her <br />immune system to make the special molecules.<br />Professor Naismith and his collaborators agreed that <br />even with the success of COVID-19 vaccines, having <br />effective treatments in the future would be crucial.<br />Professor Naismith and his collaborators agreed that <br />even with the success of COVID-19 vaccines, having <br />effective treatments in the future would be crucial.<br />The study was published in <br />the journal 'Nature Communications.' .<br />But according to the BBC, Professor Sheena Cruickshank, <br />an immunologist from the University of Manchester,<br />said the new development was, "exciting but still quite early.".<br />We need more data on efficacy and safety <br />before we move to human trials. <br />However it's very promising nonetheless <br />and the fact it may be cheaper and easier <br />to administer is a plus. Covid-19 will be, <br />unfortunately, with us for a while yet, <br />so more treatments will be needed, Professor Sheena Cruickshank, Immunologist from <br />the University of Manchester, via BBC.<br />We need more data on efficacy and safety <br />before we move to human trials. <br />However it's very promising nonetheless <br />and the fact it may be cheaper and easier <br />to administer is a plus. Covid-19 will be, <br />unfortunately, with us for a while yet, <br />so more treatments will be needed, Professor Sheena Cruickshank, Immunologist from <br />the University of Manchester, via BBC
